FindTrial
Sign In

The multicentre, prospective, controlled study on the effection and safety of individualizing immunosuppresive program according to cytochrome P450(CYP) 3A5 gene polymorphism in liver transplant patients

The multicentre, prospective, controlled study on the effection and safety of individualizing immunosuppresive program according to cytochrome P450(CYP) 3A5 gene polymorphism in liver transplant patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003204
Enrollment
Unknown
Registered
2013-05-08
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver transplantation

Interventions

2:FK506
1:cyclosporine A

Sponsors

Beijing You'An Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: In 6 liver transplant centers, we evaluate the genotypes of CYP3A5 in donor and recipient before liver transplantation. Inclusion criteria: aged 18-75 years old; able to provide informed consent; the first body / DCD in vivo liver transplantation; donor or recipient preoperative testing results for the CYP3A5*1 genotype carriers.

Exclusion criteria

Exclusion criteria: Allergic to CsA, FK506 or its ingredient; renal insufficiency; marginal donor.

Design outcomes

Primary

MeasureTime frame
CYP3A5 genotype;blood concentration;—

Countries

China

Contacts

Public ContactShichun Lu
lsc620213@yahoo.com.cn+86 13381210573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026